Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Medtronic
Harvard Business School
Express Scripts
Accenture
Fish and Richardson

Generated: August 19, 2019

DrugPatentWatch Database Preview

Claims for Patent: 7,354,902

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,354,902
Title:Recombinant lactoferrins, methods of production from plants and uses thereof
Abstract: The invention concerns the use of a recombinant nucleotide sequence containing a cDNA coding for a lactoferrin, in particular human lactoferrin, or the derived proteins, and elements enabling a plant cell to produce lactoferrin or the derived proteins, coded by said cDNA, in particular a transcription promoter and terminator identified by the plant cell transcription machinery, to transform plant cells in order to obtain, from these cells, or plants obtained therefrom, lactoferrin or derived proteins.
Inventor(s): Legrand; Dominique (Villeneuve d\'Ascq, FR), Salmon; Valerie (Montville, FR), Spik; Genevieve (Marcq en Baroeul, FR), Gruber; Veronique (Chamalieres, FR), Bournat; Philippe (Clermont-Ferrand, FR), Merot; Bertrand (Volvic, FR)
Assignee: Meristem Therapeutics S.A. (Clermont-Ferrand, FR)
Application Number:10/446,234
Patent Claims:1. A mature lactoferrin obtained by a method of producing lactoferrin comprising: (a) transforming plant cells so as to integrate a recombinant nucleotide sequence within the genome of the plant cells, the plant cells selected from the group consisting of maize, wheat, barley and rice cells, and the recombinant nucleotide sequence comprising: (i) a coding sequence for the mature lactoferrin, (ii) a transcription promoter and terminator which are operably linked to the coding sequence of (i) and are recognized by transcriptional machinery of plant cells, and (iii) a coding sequence for a signal peptide that directs secretion of recombinant peptides from plant cells, (b) expressing lactoferrin in said transformed plant cells, and (c) recovering the lactoferrin expressed in said transformed plant cells, wherein the expressed lactoferrin is mature lactoferrin.

2. The lactoferrin of claim 1, wherein the coding sequence for the lactoferrin is a coding sequence for human lactoferrin.

3. The lactoferrin of claim 1, wherein the coding sequence for a signal peptide is a sequence selected from the group consisting of a coding sequence for a signal peptide of lactoferrin, a coding sequence for the signal peptide of sweet potato sporamin A and a coding sequence for PRS (pathogenesis related protein).

4. The lactoferrin of claim 1, wherein the terminator is selected from the group consisting of the terminator polyA 35S of the CaMV (cauliflower mosaic virus), and the terminator polyA NOS of Agrobacterium tumefaciens and is located downstream of the coding sequence for the mature lactoferrin.

5. The lactoferrin of claim 1, wherein the transcription promoter is selected from the group consisting of the 35S promoter of the CaMV, the double constitutive promoter of the CaMV, the promoter pCRU of the radish cruciferin gene, the promoters pGA1 and pGA6 of Arabidopsis thaliana, the chimeric promoter super-promoter PSP of Agrobacterium tumefaciens, the rice actin promoter followed by the actin intron PAR-IRA promoter, the wheat HMWG promoter, and the maize gamma-zein promoter.

6. The lactoferrin of claim 1, wherein the recovering of the recombinant lactoferrin is by extraction followed by purification.

7. The lactoferrin of claim 1, wherein the transforming of plant cells is by means of Agrobacterium tumefaciens transformed by a vector containing the recombinant sequence.

8. The lactoferrin of claim 1, wherein: the coding sequence for the mature lactoferrin is the coding sequence for human lactoferrin, the coding sequence for a signal peptide is the coding sequence for the signal peptide of sweet potato sporamin A, the terminator is the terminator polyA 35S of the CaMV, and the transcription promoter is the wheat HMWG promoter.

9. A biomaterial or a pharmaceutical, medical, odontological, cosmetic or biotechnological composition which comprises the lactoferrin of claim 1.

10. A mature lactoferrin obtained by a method of producing lactoferrin comprising: (a) transforming plant cells so as to integrate a recombinant nucleotide sequence within the genome of the plant cells, the plant cells selected from the group consisting of maize, wheat, barley and rice cells, and the recombinant nucleotide sequence comprising: (i) a coding sequence for the mature lactoferrin, (ii) a transcription promoter and terminator which are operably linked to the coding sequence of (i) and are recognized by transcriptional machinery of plant cells, and (iii) a coding sequence for a signal peptide that directs secretion of recombinant peptides from plant cells, (b) producing transformed plants from the transformed plant cells, (c) expressing lactoferrin from said transformed plants, and (d) recovering the lactoferrin expressed from said transformed plants, wherein the expressed lactoferrin is mature lactoferrin.

11. The lactoferrin of claim 10, wherein the coding sequence for the lactoferrin is a coding sequence for human lactoferrin.

12. The lactoferrin of claim 10, wherein the coding sequence for a signal peptide is a sequence selected from the group consisting of a coding sequence for a signal peptide of lactoferrin, a coding sequence for the signal peptide of sweet potato sporamin A and a coding sequence for PRS.

13. The lactoferrin of claim 10, wherein the terminator is selected from the group consisting of the terminator polyA 35S of the CaMV, and the terminator polyA NOS of Agrobacterium tumefaciens and is located downstream of the coding sequence for the mature lactoferrin.

14. The lactoferrin of claim 10, wherein the transcription promoter is selected from the group consisting of the 35S promoter of the CaMV, the double constitutive promoter of the CaMV, the promoter pCRU of the radish cruciferin gene, the promoters pGA1 and pGA6 of Arabidopsis thaliana, the chimeric promoter super-promoter PSP of Agrobacterium tumefaciens, the rice actin promoter followed by the actin intron PAR-IRA promoter, the wheat HMWG promoter, and the maize gamma-zein promoter.

15. The lactoferrin of claim 10, wherein the recovering of the recombinant lactoferrin is by extraction followed by purification.

16. The lactoferrin of claim 10, wherein the transforming of plant cells is by means of Agrobacterium tumefaciens transformed by a vector containing the recombinant sequence.

17. The lactoferrin of claim 10, wherein: the coding sequence for the mature lactoferrin is the coding sequence for human lactoferrin, the coding sequence for a signal peptide is the coding sequence for the signal peptide of sweet potato sporamin A, the terminator is the terminator polyA 35S of the CaMV, and the transcription promoter is the wheat HMWG promoter.

18. A biomaterial or a pharmaceutical, medical, odontological, cosmetic or biotechnological composition which comprises the lactoferrin of claim 10.

Details for Patent 7,354,902

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Try a Free Trial Meristem Therapeutics S.A. (Clermont-Ferrand, FR) 2017-05-02 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Try a Free Trial Meristem Therapeutics S.A. (Clermont-Ferrand, FR) 2017-05-02 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Try a Free Trial Meristem Therapeutics S.A. (Clermont-Ferrand, FR) 2017-05-02 RX search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source

Subscribe to access the full database, or try a Free Trial

International Patent Family for US Patent 7,354,902

Country Patent Number Publication Date
World Intellectual Property Organization (WIPO) 9850543 Nov 12, 1998
United States of America 2003229925 Dec 11, 2003
United States of America 2011092411 Apr 21, 2011
United States of America 6569831 May 27, 2003
United States of America 8334254 Dec 18, 2012
Japan 2001527406 Dec 25, 2001
France 2762850 Feb 11, 2000
Country Patent Number Publication Date

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Medtronic
Julphar
Cantor Fitzgerald
UBS
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.